Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Official title: An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo
In brief: This is a multicenter, open-label study designed to evaluate the safety, tolerability and efficacy of ATI-50002 Topical Solution 0.46% in subjects with non-segmental facial vitiligo. Subjects will be required to have a clinical diagnosis of non-segmental facial vitiligo effecting at least 0.25% of total body surface area (TBSA) (excluding upper and lower eyelids, mucosal lip areas, and forehead and chin areas covered by the stereotactic positioning device for photography) with at least one area of the face with normal pigmentation. Twenty-four eligible subjects will receive ATI-50002 Topical Solution, 0.46%, BID for 24 weeks.
Ages eligible: 18 Years to 65 Years
Locations: Aclaris Investigator Site
- Encinitas, California, United States, 92024
- Los Angeles, California, United States, 90036
- Worcester, Massachusetts, United States, 01655
- Dallas, Texas, United States, 75390
- Lynchburg, Virginia, United States, 24501
Status: Unknown, not recruiting
Start date: March 19, 2018
Completion date: September 30, 2019
Identifier: ClinicalTrials.gov NCT03468855
Contacts: To learn more about this study, you or your doctor may contact Aclaris Therapeuitcs. Please refer to this study by its NCT number.
- Can Ayurveda help with vitiligo?
People have used herbs and natural remedies to treat skin conditions for centuries. Vitiligo is an auto-immune condition that causes white patches of skin to develop and expand...
- Is it possible to stop the progression of vitiligo?
It is true that vitiligo progression could be stopped in 4 out of 5 cases by the use of potent systemic corticosteroids - that is, oral medications. However, systemic corticost...
- Which diseases most commonly accompany vitiligo?
According to a 10-year study, vitiligo patients have a statistically significant higher prevalence of other autoimmune conditions and dermatological disorders: hypothyroidism...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.Copyright (C) Bodolóczki Júlia
By taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.